Ann: Completion of Placement, page-297

Arthuros. Great Post. No one has ever debated the technology. Its great. But in a small company in Biotech/Pharma/Health....the wrong management is a disaster and this management have done nothing to commercialise APAS and have had years whilst FDA was approved.

The APS deal should have been ready to go. It was not. They exhibit incompetence in management first and formost.

Then there is the debacle of the insiders selling out and then issuing themselves massively discounted stock and 1/2 price to 30% of what many shareholders paid. At least offer the shareholders a rights issue or SPP.

No they exhibit pure greed and blow out of the water what cred that had left.

This needs a buyout to get rid of the wholelot. Mgt, board everyone. Even the former CEO dumped everything...what does that tell you, no APAS deal is even close.

This sadly falls to 25c at least or lower before APAS. Thats the undiluted price of 31c adjusted.

Let these bozos and their cronie mates pay 31c when its 18c.

I bailed and will only buy post APAS....and I will be waiting a long long long time I think if the insider signals are anything to go by and mgt need a massive APAS deal not an ordinary one and thats a home run they simply cannot hit.

Sadly the technology and shareholders are victims of one of the worst and greedy mgts on ASX...

We have learned FDA and great technology with crap and greedy management = zero value

Nearly every shareholder bar the new ones in at 31c are p*ssed off and will be for some time.

ASX investors NEVER forgive management like this. In 20 years in markets, Cred takes 5 minutes to destroy and years or MASSIVE achievement to restore.

I call 20-25c and lower. Its long term average is 19c and I see no reason to think it does not belong back there. The dilution anchor starts now with a massive share overhang above from pissed off shareholders.

They need APAS and fast but what you hear from biotech is silence for months and years.

GG.